Cancer vaccines
US10251944B2 · kind B2 · utility
0Cited by
20References
42Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 17, 2017 |
| Grant date | Apr 9, 2019 |
| Priority date | — |
| Expiry date | Jan 17, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/62
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.